Regulators could not set an acceptable daily intake
JECFA, the joint WHO and FAO expert committee on food additives, reviewed Yellow 2G three times between 1974 and 1979. In 1977 a temporary intake level of 0-0.025 mg/kg body weight was assigned, but by 1979 the committee concluded that the available data were insufficient to support any intake level at all. Key gaps included the absence of multi-generation reproductive toxicity studies and incomplete metabolism data. JECFA withdrew the specifications entirely in 1984, and Yellow 2G is not listed in the WHO/FAO General Standard for Food Additives.
JECFA assigned a temporary ADI of 0-0.025 mg/kg body weight in 1977, then withdrew it in 1979, concluding no ADI could be allocated due to insufficient data.
1979Regulatory reviewWHO JECFA database, Chemical ID 3225
Multi-generation reproductive studies and embryotoxicity data were absent, and the metabolism of Yellow 2G had not been examined to a satisfactory extent, preventing a full evaluation.
1974Regulatory reviewJECFA monograph 383, WHO Food Additives Series 6
JECFA formally withdrew Yellow 2G specifications in 1984; the dye is not listed in the WHO/FAO General Standard for Food Additives.
1984RegulatoryWHO JECFA database, Chemical ID 3225
Animal studies did not find cancer, but the dataset was incomplete
Long-term feeding studies in rats (two years) and mice (80 weeks) did not produce carcinogenic effects attributable to Yellow 2G. Minor kidney changes in rats were judged to reflect spontaneous age-related degeneration rather than treatment. However, because the overall data set was incomplete when JECFA reviewed it, the absence of cancer in these particular studies is not equivalent to a full clearance.
In a two-year rat study and an 80-week mouse study, Yellow 2G did not exert a carcinogenic effect; minor kidney changes in old rats were attributed to spontaneous age-related degeneration rather than treatment.
1977AnimalJECFA monograph 448, WHO Food Additives Series 12
Short-term studies in rats (13 weeks, up to 10,000 ppm) and pigs (15 weeks, up to 500mg/kg/day) showed no serious adverse effects on growth or haematological parameters, though transient diarrhoea occurred at the highest pig doses.
1977AnimalJECFA monograph 448, WHO Food Additives Series 12
Azo dye class: hypersensitivity in aspirin-sensitive individuals
Azo dyes as a class are associated with hypersensitivity reactions including urticaria (hives), angioedema and asthma in a subset of the population. The proposed mechanism involves histamine release from basophils, partly sharing a pathway with aspirin sensitivity. The reactions are described as pseudo-allergic rather than true IgE-mediated allergy. Confirmed hypersensitivity to azo dyes is estimated to affect a small fraction of the general population but is more common in people who already react to aspirin or have chronic urticaria. Yellow 2G belongs to the same structural class as the dyes involved in these reactions.
In a single-blind placebo-controlled challenge study in patients with chronic urticaria, 5.1% of those challenged reacted positively to a mixture of azo dyes, with symptoms including urticaria and angioedema.
2021RCTHypersensitivity of azo dyes in urticaria patients, PMC9704453
In a study of perennial asthmatics challenged with aspirin and azo dyes, significant bronchoconstriction to azo dyes did occur, though less frequently than to aspirin; dye reactions were concluded to be an uncommon but real cause of bronchoconstriction.
1979ObservationalWeber et al., Journal of Allergy and Clinical Immunology, 1979
Tartrazine, another azo dye, is estimated to cause hypersensitivity in 20-50% of individuals already sensitive to aspirin; Yellow 2G shares the azo bond structural feature associated with cross-reactivity.
1990ObservationalTartrazine sensitivity review, PubMed PMID 2239641